Ad Astra Awards
Ad Astra Journal
Science library
White book
University rankings
Who's who
Publications
Theses and dissertations
Ad Astra association
 
Press releases
News
Events
Funding opportunities
 
Login
Registration
 
>> Românã
 
   
 

Banciu, M., Fens, M. H. M., Storm, G., Schiffelers, R. M. . Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. . J. Control. Release. , 127(2), pp. 131-6., 2008.

Abstract: Prednisolone disodium phosphate (PLP) encapsulated in long-circulating liposomes (LCL) (LCL-PLP) inhibited tumor growth by 8090%
after a single dose of 20 mg/kg, whereas PLP in the free form was completely ineffective at the same single dose. To generalize our findings with
LCL-PLP, the antitumor activity and side effects of LCL containing synthetic glucocorticoids (LCL-GC) other than PLP were investigated. In
addition to PLP, budesonide disodium phosphate, dexamethasone disodium phosphate, and methylprednisolone disodium phosphate were selected
based on the difference in their potency to activate the human glucocorticoid receptor. The present study shows that the tumor localization of each
GC is governed by the transport capacity of the LCL composed of dipalmitoylphosphatidylcholine, cholesterol, and polyethylene glycol 2000-
distearoylphosphatidylethanolamine in a molar ratio of 1.85:1.0:0.15. The antitumor potency of the LCL-GC strongly depends on the potency of
the type of GC encapsulated. LCL-encapsulated budesonide disodium phosphate (LCL-BUP) had the highest antitumor activity which is likely
due to the much higher potency of BUP encapsulated in LCL versus the other three GC types. The high potency of LCL-BUP confers the risk for
occurrence of strong side effects. However, at the dose of 3 mg/kg, LCL-BUP was highly efficacious without the occurrence of adverse effects.

Keywords: Long-circulating liposomes; Glucocorticoids; Antitumor activity; Side effects; Cancer

Posted by Manuela Banciu

Back

   
© Ad Astra 2001-2013